Boston University Alzheimer's Disease Research Center

波士顿大学阿尔茨海默病研究中心

• 批准号: 10652548
• 负责人: Ann C. McKee
• 金额: $ 322.91万
• 依托单位: BOSTON UNIVERSITY MEDICAL CAMPUS
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10652548
• 关键词: Acceleration; Address; Advocacy; Affect; Alzheimer' s Disease; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Amyloid; Biological; Biological Markers; Biometry; Blood; Blood Vessels; Books; Boston; Brain Concussion; Cerebral Amyloid Angiopathy; Clinic; Clinical; Clinical Data; Cognitive; Collaborations; Communities; Consultations; Data; Data Collection; Data Set; Deposition; Development; Early identification; Electroencephalography; Ensure; Environmental Risk Factor; Exposure to; Foundations; Framingham Heart Study; Funding; Future; General Population; Genetic; Goals; Grant; Growth; Heart; Heterogeneity; Impaired cognition; Individual; Infrastructure; Late Effects; Lewy Body Disease; Liquid substance; Longevity; Magnetic Resonance Imaging; Mission; Modeling; Molecular Profiling; Nature; Participant; Pathologic; Pathology; Phenotype; Positioning Attribute; Positron-Emission Tomography; Prevention; Privatization; Qualifying; Recommendation; Research; Research Personnel; Research Support; Resources; Risk; Risk Factors; Sampling; Scientist; Secure; Source; Specimen; Spinal Puncture; Strategic vision; Tauopathies; Training; United States National Institutes of Health; Universities; Vascular Diseases; Women' s Health; abeta deposition; age related; analytical tool; biomarker discovery; black women; career development; catalyst; chronic traumatic encephalopathy; cohort; community engagement; contact sports; data management; digital; digital health; education research; experience; follow-up; genetic profiling; head impact; health assessment; high risk; human subject; innovation; interest; military service; molecular phenotype; motor neuron degeneration; neuroimaging; neuroinflammation; neuropathology; next generation; outreach; outreach program; prevent; programs; protein TDP-43; public-private partnership; recruit; research clinical testing; research study; statistics; symposium; tau Proteins; white matter

The Boston University Alzheimer's Disease Research Center (BU ADRC) is committed to the goals and strategies of NAPA including: to prevent and effectively treat AD and AD related dementias (ADRD) by 2025 by expanding AD/ADRD research; to accelerate efforts to identify early and pre-symptomatic stages of AD/ADRD; and to educate the public about AD/ADRD. BU ADRC research themes are congruent with NIH AD/ADRD Research Summit recommendations including: 1) research on heterogeneity and the multifactorial nature of AD/ADRD; 2) molecular profiling of existing and new cohorts; and 3) developing new public-private partnerships. We operationalize our mission through 7 tightly integrated cores: Administrative, Clinical (CC), Data Management and Statistics (DMS), Biomarker, Neuropathology (NPC), Outreach/Recruitment, Engagement (ORE), Genetics and Molecular Profiling (GMP) and a research education component (REC). The Cores are focused on cutting edge research, proactive community engagement, training the next generation of AD/ADRD clinicians and researchers, and sharing key material, data, and expertise both among key partners and with the community at large. The BU ADRC has made significant contributions to the remarkable growth of AD/ADRD research nationally and has actively contributed participants, biological samples, clinical data, and scientific expertise to all major national AD/ADRD research initiatives. The BU ADRC has been the catalyst for exciting new research on genetic and lifespan environmental risk factors and AD/ADRD, particularly vascular risk and exposure to repetitive head impacts (RHI) from contact sports, military service and other sources. Major BU ADRC research themes include studies on RHI from contact sports and military service and risk for AD/ADRD, including chronic traumatic encephalopathy (CTE) and deep phenotyping AD/ADRD heterogeneity with a range of complementary innovative approaches including digital and EEG phenotyping; neuropathology; genetics; biostatistical modelling; biomarker discovery; and molecular profiling. The BU ADRC will build on this strong record of accomplishment to support new research and educate the next generation of AD/ADRD scientists. The BU ADRC will also support high risk high gain innovative developmental projects focused on NAPA and NIA strategic goals and utilize our collective expertise and experience to facilitate career development of investigators with diverse backgrounds. The BU ADRC will develop new partnerships and enhance current partnerships with other ADRCs and national research programs, foundations, advocacy groups and private organizations in our quest to prevent and treat AD/ADRD. Exposure to RHI is associated with CTE and a wide range of other AD/ADRD pathologies. As recognized leaders in this space, we are uniquely positioned to support research on genetic and other risks factors and study how RHI affects the clinical course, biomarker profile, and clinical-pathological features of AD/ADRD including CTE.

波士顿大学阿尔茨海默病研究中心（BU ADRC）致力于实现这些目标， 国家适应行动方案的战略，包括：到2025年预防和有效治疗AD和AD相关痴呆， 扩大AD/ADRD研究;加快努力，以确定AD/ADRD的早期和症状前阶段; 并教育公众有关AD/ADRD的知识。BU ADRC研究主题与NIH AD/ADRD一致 研究峰会的建议包括：1）研究异质性和多因素的性质， AD/ADRD; 2）现有和新队列的分子特征分析;以及3）开发新的公私合作伙伴关系 伙伴关系。我们通过7个紧密集成的核心来实现我们的使命：行政，临床（CC）， 数据管理和统计（DMS）、生物标志物、神经病理学（NPC）、外展/招募， 参与（ORE），遗传学和分子分析（GMP）和研究教育部分（REC）。 核心团队专注于前沿研究、积极主动的社区参与、培训下一个 AD/ADRD临床医生和研究人员的一代，并分享关键材料，数据和专业知识， 主要合作伙伴和整个社区。BU ADRC为以下方面做出了重大贡献： AD/ADRD研究在全国范围内显着增长，并积极贡献参与者，生物 样本，临床数据和科学专业知识，所有主要的国家AD/ADRD研究计划。的BU ADRC一直是令人兴奋的遗传和寿命环境风险因素新研究的催化剂， AD/ADRD，特别是血管风险和接触接触性运动、军事的重复性头部撞击（RHI） 服务和其他来源。BU ADRC的主要研究主题包括接触性运动中的RHI研究， 军事服务和AD/ADRD的风险，包括慢性创伤性脑病（CTE）和深 表型AD/ADRD异质性与一系列互补的创新方法，包括数字 和EEG表型;神经病理学;遗传学;生物统计建模;生物标志物发现;和分子生物学 侧写BU ADRC将在这一良好的成就记录基础上，支持新的研究， 培养下一代AD/ADRD科学家。BU ADRC还将支持高风险高收益 创新的发展项目侧重于国家适应行动方案和国家影响评估战略目标，并利用我们的集体专长 和经验，以促进不同背景的调查人员的职业发展。BU ADRC将 发展新的伙伴关系，加强与其他发展成果中心和国家研究机构的现有伙伴关系 项目、基金会、倡导团体和私人组织，以寻求预防和治疗AD/ADRD。 暴露于RHI与CTE和广泛的其他AD/ADRD病理相关。承认的 作为这一领域的领导者，我们在支持遗传和其他风险因素的研究方面具有独特的地位， 研究RHI如何影响AD/ADRD的临床病程、生物标志物特征和临床病理特征 包括CTE。

项目成果

Visualizing reactive astrocyte-neuron interaction in Alzheimer's disease using 11C-acetate and 18F-FDG.

• DOI: 10.1093/brain/awad037
• 发表时间: 2023-04
• 期刊: Brain : a journal of neurology
• 作者: Min-Ho Nam;H. Ko;Dongwoo Kim;Sangwon Lee;Yongmin Mason Park;Seung Jae Hyeon;Woojin Won;Jee-in Chung;Seon yoo Kim;Hanhee Jo;Kyeongtaek Oh;Young-eun Han;G. Lee;Y. Ju;Hyowon Lee;Hyunjin Kim;Jaejun Heo;Mridula Bhalla;Ki Jung Kim;Jea Kwon;T. Stein;Mingyu Kong;Hyunbeom Lee;Seung Eun Lee;Soo-Jin Oh;Joong-Hyun Chun;Mi-Ae Park;Ki Duk Park;Hoon Ryu;M. Yun;C. J. Lee

Accelerated Breakdown of Phosphatidylcholine and Phosphatidylethanolamine Is a Predominant Brain Metabolic Defect in Alzheimer's Disease.

• DOI: 10.3233/jad-230061
• 发表时间: 2023-05
• 期刊: Journal of Alzheimer's disease : JAD
• 作者: J. Blusztajn;B. Slack

Amyloid PET ordering practices in a memory disorders clinic.

• DOI: 10.1002/trc2.12333
• 发表时间: 2022
• 期刊: ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS
• 影响因子: 4.8
• 作者: Turk, Katherine W;Vives-Rodriguez, Ana;Schiloski, Kylie A;Marin, Anna;Wang, Ryan;Singh, Prabhjyot;Hajos, Gabor P;Powsner, Rachel;DeCaro, Renee;Budson, Andrew E
• 通讯作者: Budson, Andrew E

Three dimensional evaluation of cerebrovascular density and branching in chronic traumatic encephalopathy.

• DOI: 10.1186/s40478-023-01612-y
• 发表时间: 2023-07-25
• 期刊: Acta neuropathologica communications
• 影响因子: 7.1

Educating students while recruiting underrepresented populations for Alzheimer's disease research: the Student Ambassador Program.

• DOI: 10.1186/s12909-022-03749-1
• 发表时间: 2022-10-05
• 期刊: BMC MEDICAL EDUCATION
• 影响因子: 3.6
• 作者: DeCaro, Renee;O'Connor, Maureen K.;DiTerlizzi, Christina;Sekyi-Appiah, Nana;Polk, John;Budson, Andrew E.
• 通讯作者: Budson, Andrew E.